Neon Therapeutics and Apexigen start Phase IIb combination trial for melanoma

Immuno-oncology firm Neon Therapeutics has partnered with biopharmaceutical company Apexigen to investigate its NEO-PV-01 in combination with APX005M in a Phase IIb trial to treat patients with metastatic melanoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news